Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Molecular and Structural Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1440654
This article is part of the Research Topic Xenosensors as the targets of endocrine-disrupting chemicals View all 3 articles

Small phenolic compounds as potential endocrine disruptors interacting with estrogen receptor alpha

Provisionally accepted
  • Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czechia

The final, formatted version of the article will be published soon.

    The human body is regularly exposed to simple catechols and small phenols originating from our diet or as a consequence of exposure to various industrial products (e.g., cigarette smoke). Several biological properties have been associated with these compounds such as antioxidant, anti-inflammatory, or antiplatelet activity. Less explored is their potential impact on the endocrine system, in particular through interaction with the alpha isoform of the estrogen receptor (ERα). In this study, human breast cancer cell line MCF-7/S0.5 was employed to investigate the effects on ERα of 22 closely chemically related compounds (15 catechols and 7 phenols and their methoxy derivatives), to which humans are widely exposed. ERα targets genes ESR1 (ERα) and TFF1, both on mRNA and protein level, were chosen to study the effect of the tested compounds on the mentioned receptor. A total of 7 compounds seemed to impact mRNA and protein expression similarly to estradiol (E2). The direct interaction of the most active compounds with the ERα ligand binding domain (LBD) was further tested in cell-free experiments using the recombinant form of the LBD, and 4-chloropyrocatechol was shown to behave like E2 with about 1/3 of the potency of E2. Our results provide evidence that some of these compounds can be considered potential endocrine disruptors interacting with ERα.

    Keywords: Endocrine disruptor, Xenobiotic, Catechol, Estrogenicity, Cytotoxicity

    Received: 29 May 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Alva-Gallegos, Jirkovský, Mladěnka and Carazo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Alejandro Carazo, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czechia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.